How Long Can You Live With Stomach Cancer by Stage?

Stomach cancer survival varies dramatically by stage, ranging from roughly 90% or higher five-year survival for the earliest cases down to a median of just a few months for cancer that has already spread to distant organs. Those numbers represent population averages, though, and the real answer for any individual depends on a tangle of factors: age, overall health, the tumor’s biology, the type of treatment received, and even the country where you’re diagnosed. Understanding what the stage-by-stage statistics actually mean, and where they fall short, can help you have more useful conversations with an oncologist.

Stage I Survival

Stage I stomach cancer is the most favorable diagnosis you can receive, and the numbers reflect it. A large Japanese registry covering surgically treated patients reported five-year overall survival rates of about 90% for stage IA and 83% for stage IB.¹ A Chinese single-institution study using the same modern staging system found similar figures: 94.5% for IA and 88.4% for IB.² These rates generally hold up well over time. A study focused specifically on early gastric cancer treated with curative surgery found overall survival rates of about 95% at five years, roughly 88% at ten years, and 77% at fifteen years.³

That long-term data is worth paying attention to. A person diagnosed at stage I and successfully treated may eventually face greater risks from ordinary age-related causes than from their original cancer. The same study noted that male patients had measurably lower survival than female patients, with the gap widening over time: roughly a 4% difference at five years, growing to about 15% at fifteen years.³ That difference likely reflects the general survival gap between men and women rather than anything specific to stomach cancer biology.

Stage II Survival

At stage II, the tumor has grown deeper into the stomach wall or spread to a small number of nearby lymph nodes. Five-year survival drops noticeably compared to stage I, but more than half of patients are still alive at the five-year mark. The Japanese registry data placed five-year survival at about 78% for stage IIA and 68% for stage IIB.¹ The Chinese study reported nearly identical numbers: 78% for IIA and about 71% for IIB.²

One quirk of stage II worth understanding: the combination of tumor depth and lymph node involvement matters more than either alone. Research has found that shallow tumors (confined to the inner stomach lining) that have already reached multiple lymph nodes can carry a worse outlook than deeper tumors with fewer nodes involved, even when both are classified as stage II. A study of this pattern suggested that these shallow-but-node-positive cases may benefit from adjuvant chemotherapy after surgery, even though their T-stage alone might not seem to warrant it.⁴ The point is that stage II is not a single entity with a single prognosis. The substage breakdown matters, and your oncologist may recommend more or less aggressive treatment depending on which version of stage II you have.

Stage III Survival

Stage III represents locally advanced disease, and this is where survival rates drop sharply. The Japanese registry reported five-year survival at about 59% for IIIA, 46% for IIIB, and 30% for IIIC.¹ The Chinese study found somewhat lower numbers for the later substages: about 54% for IIIA, 33% for IIIB, and 19% for IIIC.² The difference between these two datasets is real and reflects how outcomes vary by treatment approach, patient population, and health-care system. Neither set is “wrong.” They illustrate the range you might encounter depending on where and how you’re treated.

A systematic review of stage I through III patients found that the majority of studies showed some survival benefit from adding chemotherapy after surgery, though the strength of that evidence varied. About 40% of the reviewed studies demonstrated a clear, statistically significant advantage for surgery plus adjuvant chemotherapy over surgery alone.⁵ That said, nearly all studies pointed in the same favorable direction, even when the margin did not reach statistical significance. For stage III in particular, combination treatment with chemotherapy has become the standard approach in most treatment centers.

Stage IV and Metastatic Disease

Stage IV stomach cancer, meaning the cancer has spread to distant organs like the liver, lungs, or the peritoneum (the lining of the abdominal cavity), carries the most difficult outlook. The Japanese registry reported a five-year survival rate of about 14% for stage IV patients who underwent surgery.¹ A population-based study found that compared to localized disease, the risk of dying from stomach cancer was roughly 52 times higher for patients with distant-stage disease.⁶

Median survival for metastatic gastric cancer tends to be measured in months rather than years. A U.S. population study found that median overall survival was about six months for patients aged 44 and younger, dropping to roughly three months for those 75 and older.⁷ Those are median figures, meaning half the patients lived longer. Some stage IV patients, particularly those with limited metastases and good overall fitness, do survive considerably longer, especially with newer treatment approaches. But the gap between stage IV and the earlier stages is enormous and unmistakable.

Why These Numbers Vary So Much by Country

If you compare stomach cancer survival data from Japan to data from Western countries, the Japanese numbers look significantly better at almost every stage. Japan has reported five-year survival rates that are considerably higher than those seen in Europe or North America.⁸ One study directly comparing Japanese and German patients with gastric cancer found a five-year survival rate of 77% in the Japanese group versus 44% in the German group.⁹

Several factors explain this. Japan and South Korea have widespread screening programs that catch cancer earlier, when it is most treatable. In these countries, a large portion of diagnoses come at stage I, whereas in Western countries where screening is not routine, the disease is more often found at advanced stages. Surgical technique also plays a role. Japanese surgeons routinely perform more extensive lymph node removal, and they have decades of high-volume experience with gastric surgery that builds institutional expertise. After accounting for differences in tumor stage, patient age, and other factors, the same Japanese-German comparison found the survival gap narrowed considerably but did not disappear entirely, suggesting the treatment center itself carries independent prognostic weight.⁹ If you’re reading survival statistics, always check where the data comes from, because a Japanese registry figure and a U.S. registry figure may not be directly comparable.

The Factors That Move Your Odds Beyond Stage

Stage is the single strongest predictor of survival, but it is far from the only one. Several other factors can meaningfully shift your individual outlook.

Tumor biology matters. The molecular characteristics of a tumor, such as whether it overexpresses the HER2 protein or has a specific immune marker profile, influence both treatment options and prognosis. One study found that patients whose tumors lacked both HER2 overexpression and PD-L1 positivity had a median overall survival of about 78 months, while those with HER2 overexpression and PD-L1 positivity had a median of 47 months, and those with HER2 overexpression but no PD-L1 had just 15 months.¹⁰ These molecular features are increasingly guiding treatment decisions, particularly around targeted therapies and immunotherapy.

Body composition and physical fitness also carry weight. A meta-analysis found that patients with low skeletal muscle mass (sarcopenia) before surgery had significantly worse overall and disease-free survival compared to patients with normal muscle mass.¹¹ In older patients, the combination of frailty and sarcopenia was particularly harmful. A study of elderly gastric cancer patients found that those with both conditions faced roughly three times the risk of death compared to those with neither.¹² For very elderly patients (85 and older), a study identified overall physical condition score and clinical stage as the two strongest independent predictors of survival, more so than specific tumor features.¹³

Surgical quality also matters. More extensive lymph node dissection during surgery (known as D2 lymphadenectomy) has been associated with better survival after adjusting for other factors. One nationwide study found an adjusted hazard ratio of 0.81, meaning roughly a 19% lower risk of death, for patients who received the more thorough lymph node removal.¹⁴ The benefit was especially clear for cancers in the lower part of the stomach, where five-year survival was about 60% with extensive node removal versus 42% without.¹⁴

Your Odds Improve the Longer You Survive

One of the most important and least-understood aspects of cancer statistics is conditional survival. The five-year survival rate you see quoted at diagnosis describes your chances starting from day one. But if you’ve already survived one, two, or three years, your odds of reaching the five-year mark improve significantly, because the people in the original statistics who died early are no longer in the calculation.

A multi-institutional Chinese study found that the five-year probability of disease-specific survival started at about 49% right after surgery. But for patients who had already survived one year, it rose to about 60%. After two years of survival, it jumped to about 75%. And for patients who made it to three years, the probability of surviving another five reached roughly 86%.¹⁵ A separate study using both Eastern and Western datasets reported a similar pattern, with the five-year conditional probability of overall survival climbing from about 42% at the time of surgery to 80% at three years out.¹⁶

This effect is strongest for patients who started with the worst prognoses. A patient initially diagnosed with stage IIIC disease who is still alive three years after surgery has seen their statistical outlook improve far more than a stage IA patient in the same timeframe, because the stage IA patient’s risk was already low to begin with. One study found a median increase in the five-year disease-specific survival probability of about 32 percentage points for three-year survivors compared to their prediction at the time of surgery.¹⁷ If you’re past the first few years after treatment and looking for reassurance, conditional survival data is more relevant to your situation than the baseline statistics you were quoted at diagnosis.

What Happens When Cancer Comes Back

For patients who undergo curative surgery, recurrence is the primary concern during the surveillance period. When stomach cancer does come back, the pattern and timing of recurrence both influence how much longer a patient is likely to live.

A study of patients who recurred after curative gastrectomy found a median post-recurrence survival of about eight months. Patients with a single site of recurrence, whether in lymph nodes, the peritoneum, or a distant organ, survived a median of about ten months. Those with recurrence at multiple sites simultaneously had a median of only about four months.¹⁸ Timing also mattered. Patients whose cancer returned within the first year after surgery tended to have had more advanced disease originally and were more likely to show features like invasion into nerves or blood vessels.¹⁹

After recurrence, whether the patient receives chemotherapy or other active treatment is itself a strong predictor of subsequent survival. Research has identified palliative treatment only (rather than active anti-cancer therapy) as an independent risk factor for shorter survival in both early and late recurrence groups.²⁰ This does not mean treatment always works, but it underscores that recurrence is not automatically a terminal event. Some patients with limited recurrence can still be treated aggressively.

How Newer Therapies Are Changing the Picture

The survival statistics available in most databases reflect patients treated years ago, because it takes time for five-year outcomes to accumulate. Treatment has evolved considerably in recent years, particularly for advanced disease. Immunotherapy, which helps the immune system recognize and attack cancer cells, has produced meaningful gains for some subsets of stomach cancer patients.

In advanced gastric cancer that lacks HER2 overexpression, the addition of the immunotherapy drug nivolumab to standard chemotherapy improved overall survival compared to chemotherapy alone in a large international trial. For HER2-positive advanced disease, adding the immunotherapy pembrolizumab to the combination of trastuzumab and chemotherapy significantly improved response rates as a first-line treatment.²¹ These are incremental improvements measured in months for most patients, not cures. But for a disease where advanced-stage survival has historically been measured in months, even modest extensions matter, and the field is moving quickly.

Neoadjuvant therapy, meaning treatment given before surgery to shrink the tumor, has also emerged as a standard approach for locally advanced disease near the junction of the stomach and esophagus. Three-year overall survival rates of roughly 50-55% have been reported with either neoadjuvant chemotherapy or chemoradiation for these tumors, with the degree of tumor response being highly predictive of long-term outcome.²² Patients whose tumors responded well to preoperative treatment had substantially better survival than those whose tumors showed no response.

The Role of Palliative Care

Palliative care is frequently misunderstood as giving up, but the evidence suggests the opposite. For advanced gastric cancer, early palliative care, started alongside active treatment rather than after it fails, can relieve symptoms more effectively and may even improve a patient’s fitness enough to tolerate further anti-cancer therapy.²³

There is also a timing problem in the other direction. A study of end-of-life decision-making for patients with esophageal or gastric cancer found that the decision to shift focus to palliative care was made late or not at all in about half of patients. Those whose transition happened earlier were more likely to spend their final days at home or in specialized palliative care settings rather than in hospitals, suggesting better end-of-life care overall.²⁴ For patients with stage IV disease or advanced-stage recurrence, early conversations about palliative support are not a sign of hopelessness but a practical step that tends to improve quality of life during whatever time remains.

Living After Gastrectomy

Survival statistics capture whether someone is alive, but they say nothing about how they’re living. Stomach cancer treatment frequently involves removing part or all of the stomach, and the type of surgery affects daily life in concrete ways.

Patients who kept part of their stomach (subtotal gastrectomy) generally reported better quality of life than those who had the entire organ removed. One study found significantly better functional scores at one year for the subtotal group, while the total gastrectomy group did not show meaningful quality-of-life improvement compared to before their surgery.²⁵ A separate study found no significant difference in most functional areas and overall health between the two groups, but did note that patients who had a total gastrectomy experienced worse difficulty swallowing and greater eating restrictions.²⁶

After any gastrectomy, most patients need to eat smaller, more frequent meals and may struggle with nutrient absorption, weight loss, and dumping syndrome, where food passes too quickly into the small intestine and causes nausea, cramping, or dizziness. These effects tend to improve over time but rarely disappear entirely. For patients weighing treatment decisions, the location and extent of the tumor often dictates whether a subtotal gastrectomy is feasible, but when the choice exists, preserving part of the stomach tends to translate into a better day-to-day experience without compromising long-term survival.